Provectus Biopharmaceuticals (PVCT) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 11, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-36457
Entity Registrant Name	PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000315545
Entity Tax Identification Number	90-0031917
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	10025 Investment Drive
Entity Address, Address Line Two	Suite 250
Entity Address, City or Town	Knoxville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37932
City Area Code	866
Local Phone Number	594-5999
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		419,447,119

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 173,614	$ 682,984
Restricted cash	2,307,395	2,423,958
Short-term receivables	3,050	5,107
Prepaid expenses and other current assets	227,908	329,908
Total Current Assets	2,711,967	3,441,957
Equipment and furnishings, less accumulated depreciation of $94,396 and $91,178, respectively	28,618	31,836
Operating lease right-of-use asset	15,177	39,563
Total Assets	2,755,762	3,513,356
Current Liabilities:
Accounts payable	1,597,496	1,287,459
Deposit for purchase of Series D-1 Preferred Stock		150,000
Unearned grant revenue	2,312,395	2,500,000
Other accrued expenses	2,185,761	2,002,486
Accrued interest	35,856	10,578
Accrued interest - related parties	10,044	6,044
Notes payable	154,925	238,452
Convertible notes payable	1,310,000	1,260,000
Convertible notes payable - related parties	200,000	200,000
Operating lease liability	18,203	45,617
Total Current Liabilities	7,824,680	7,700,636
Commitments, contingencies, and litigations (Note 11)
Stockholders’ Deficiency:
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 419,447,119 shares issued and outstanding at March 31, 2022 and December 31, 2021	419,447	419,447
Additional paid-in capital	241,590,054	241,440,106
Accumulated other comprehensive loss	(35,183)	(34,467)
Accumulated deficit	(247,064,880)	(246,033,958)
Total Stockholders’ Deficiency	(5,068,918)	(4,187,280)
Total Liabilities and Stockholders’ Deficiency	2,755,762	3,513,356
Series D Convertible Preferred Stock [Member]
Stockholders’ Deficiency:
Preferred stock value	12,373	12,373
Series D-1 Convertible Preferred Stock [Member]
Stockholders’ Deficiency:
Preferred stock value	$ 9,271	$ 9,219

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 94,396	$ 91,178
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common Stock, Shares, Outstanding	419,447,119	419,447,119
Common shares, Issued	419,447,119	419,447,119
Series D Convertible Preferred Stock [Member]
Preferred stock, shares authorized	12,374,000	12,374,000
Preferred stock, shares issued	12,373,247	12,373,247
Preferred Stock, Shares Outstanding	12,373,247	12,373,247
Preferred stock, liquidation preference per share	$ 14,164,889	$ 14,164,889
Series D-1 Convertible Preferred Stock [Member]
Preferred stock, shares authorized		11,241,000
Preferred stock, shares issued	9,270,860	9,218,449
Preferred stock, liquidation preference per share	$ 106,132,320	$ 105,532,804

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Grant Revenue	$ 187,605
Operating Expenses:
Research and development	671,116	655,144
General and administrative	516,547	525,532
Total Operating Expenses	1,187,663	1,180,676
Total Operating Loss	(1,000,058)	(1,180,676)
Other Income/(Expense):
Interest income and interest expense	(30,864)	(489,274)
Total Other Expense, Net	(30,864)	(489,274)
Net Loss	$ (1,030,922)	$ (1,669,950)
Basic and Diluted Loss Per Common Share	$ 0	$ 0
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	419,447,119	402,184,815

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Net Loss	$ (1,030,922)	$ (1,669,950)
Other Comprehensive Loss:
Foreign currency translation adjustments	(716)	837
Total Comprehensive Loss	$ (1,031,638)	$ (1,669,113)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Balance at January 1, 2021	$ (4,187,280)
Net loss	(1,030,922)	$ (1,669,950)
Balance at March 31, 2021	$ (5,068,918)
Preferred Stock [Member] | Series D Convertible Preferred Stock [Member]
Balance, shares	12,373,247
Balance, shares	12,373,247
Preferred Stock [Member] | Series D-1 Convertible Preferred Stock [Member]
Balance, shares	9,218,449
Series D-1 Preferred Stock issued for cash, shares	52,411
Balance, shares	9,270,860
Preferred Stock [Member] | Series B Preferred Stock [Member]
Balance, shares		100
Common stock issued upon exercise of warrants, shares
Common stock, shares
Balance, shares		100
Common Stock [Member]
Balance, shares	419,447,119	398,807,037
Common stock issued upon exercise of warrants, shares		4,500,000
Common stock, shares		250,000
Balance, shares	419,447,119	403,557,037

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash Flows From Operating Activities:
Net loss	$ (1,030,922)	$ (1,669,950)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		19,750
Non-cash lease expense	24,386	20,006
Depreciation	3,218	3,216
Changes in operating assets and liabilities
Short term receivables	2,143	(515)
Prepaid expenses	101,964	45,822
Accounts payable	309,732	(10,927)
Unearned grant revenue	(187,605)
Other accrued expenses	183,001	12,252
Operating lease liability	(27,414)	(21,096)
Accrued interest expense	29,278	487,962
Net Cash Used In Operating Activities	(592,219)	(1,113,480)
Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable	50,000	1,200,000
Repayment of short-term note payable	(83,527)	(74,417)
Proceeds from exercise of warrants		239,850
Net Cash (Used In) Provided By Financing Activities	(33,527)	1,365,433
Effect of exchange rates on cash, cash equivalents, and restricted cash	(187)	587
Net (Decrease) Increase In Cash, Cash Equivalents, and Restricted Cash	(625,933)	252,540
Cash, Cash Equivalents, and Restricted Cash, Beginning of Period	3,106,942	97,231
Cash, Cash Equivalents, and Restricted Cash, End of Period	2,481,009	349,771
Cash and cash equivalents	173,614	349,771
Restricted cash	2,307,395
Cash paid during the period for:
Interest
Income taxes

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	1. Business Organization, Nature of Operations and Basis of Presentation Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or the “Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases, based on a class of small molecules called halogenated xanthenes (“HXs”) that is entirely owned by the Company. Our lead HX molecule is named rose bengal sodium (“RBS”). A second synthesized HX molecule is 4,5,6,7-tetrabromo-3′,6′-dihydroxy-2′,4′,5′,7′-tetraiodo-3H-spiro[isobenz- ofuran-1,9′-xanthen]-3-one. ● Oncology: ® Oral formulations of cGMP RBS are also undergoing preclinical study as prophylactic and therapeutic treatments for high-risk and refractory adult solid tumor cancers, such as head and neck, breast, colorectal, and testicular cancers. In vivo ● Pediatric Oncology: ● Hematology: In vivo ● Virology: In silico In vitro ● Microbiology: In vitro ● Ophthalmology: ● Dermatology: ® ● Animal Health: To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2021 filed with the SEC on March 29, 2022. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. SARS-CoV-2 was reportedly first identified in late-2019 and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the SARS-CoV-2 pandemic, many companies have experienced disruptions of their operations and the markets they serve. The Company has taken several temporary precautionary measures intended to help ensure the well-being of its employees and contractors and to minimize business disruption. The Company considered the impact of SARS-CoV-2 pandemic on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s results of operations and financial position at March 31, 2022. The full extent of the SARS-CoV-2 pandemic impacts on the Company’s operations and financial condition is uncertain. The Company has experienced slower than normal enrollment and treatment of patients, and a prolonged SARS-CoV-2 pandemic could have a material adverse impact on the Company’s business and financial results, including the timing and ability of the Company to raise capital, initiate and/or complete current and/or future preclinical studies and/or clinical trials, disrupt the Company’s regulatory activities, and/or have other adverse effects on the Company’s clinical development.

Liquidity and Going Concern

Liquidity and Going Concern	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern The Company’s cash, cash equivalents, and restricted cash were $ 2,481,009 at March 31, 2022 which includes the $ 2,307,395 of restricted cash resulting from a grant received from the State of Tennessee. The Company’s working capital deficiency was $ 5,112,713 and $ 4,258,679 as of March 31, 2022 and December 31, 2021, respectively. The Company continues to incur significant operating losses. Management expects that significant on-going operating expenditures will be necessary to successfully implement the Company’s business plan and develop and market its products. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these unaudited condensed consolidated financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to develop PV-10, PH-10, and/or any other halogenated xanthene-based drug products, and to raise additional capital. The Company plans to access capital resources through possible public or private equity offerings, including the 2021 financing (see Note 5), exchange offers, debt financings, corporate collaborations, or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, although no assurance can be provided that it will continue to be successful in the future. If the Company is unable to raise sufficient capital, it will not be able to pay its obligations as they become due. The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, the Company cannot assure that it will be successful in co-developing, licensing, and/or commercializing PV-10, PH-10, and/or any other halogenated xanthene-based drug candidate developed by the Company or entering into any financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2022 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, the Company cannot provide assurance that it will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

Significant

Significant	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Significant	3. Significant Accounting Policies Since the date the Company’s December 31, 2021 consolidated financial statements were issued in its 2021 Annual Report, there have been no material changes to the Company’s significant accounting policies, except as disclosed below. Recently Adopted Accounting Standards In October 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-10 “Codification Improvements” On May 3, 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of March 31, 2022 and December 31, 2021, the Company’s cash equivalents consist of Treasury bills of $ 42,594 . Restricted Cash Restricted cash consists of a grant award of $ 2,500,000 192,605 Cash Concentrations Cash, cash equivalents, and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $ 250,000 2,231,009 2,856,942 Reclassifications Certain prior year balances have been reclassified in order to conform to current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share. Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares March 31, March 31, 2022 2021 Warrants 512,500 82,764,164 Options 3,625,000 4,800,000 Convertible preferred stock 105,081,847 65,666 2021 unsecured convertible notes 5,436,408 - Total potentially dilutive shares 114,655,755 87,629,830

Other Accrued Expenses

Other Accrued Expenses	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Other Accrued Expenses	4. Other Accrued Expenses The following table summarizes the other accrued expenses at March 31, 2022 and December 31, 2021: Schedule of Other Accrued Expenses March 31, 2022 December 31, 2021 Accrued payroll and taxes $ 244,349 $ 174,533 Accrued vacation 50,859 42,871 Accrued directors’ fees 1,656,839 1,560,589 Accrued other expenses 233,714 224,493 Total Other Accrued Expenses $ 2,185,761 $ 2,002,486

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Convertible Notes Payable	5. Convertible Notes Payable 2021 Financing Schedule of Convertible Notes Payable Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2022 $ 1,260,000 $ 200,000 $ 1,460,000 Issued 50,000 - 50,000 Balance as of March 31, 2022 $ 1,310,000 $ 200,000 $ 1,510,000 For further details on the terms of the 2021 Notes, refer to our Form 10-K as filed with the SEC on March 29, 2022. As of March 31, 2022, the Company had received 2021 Notes proceeds of $ 1,510,000 200,000

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable The Company obtained short-term financing from AFCO Insurance Premium Finance for our commercial insurance policies. As of March 31, 2022 and December 31, 2021, the balance of the note payable was $ 154,925 238,452

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions During the three months ended March 31, 2022 and 2021, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $ 42,400 and $ 84,800 , respectively, for services rendered. Director fees for Mr. Horowitz for the three months ended March 31, 2022 and 2021 were $ 18,750 and $ 18,750 , respectively. Accrued director fees for Mr. Horowitz as of March 31, 2022 and December 31, 2021 were $ 300,000 and $ 281,250 , respectively. Total amount owed to Capital Strategists as of March 31, 2022 and December 31, 2021 were $ 127,200 . Mr. Horowitz serves as both COO and a Director, of the Company. See Note 5 for details of other related party transactions. Director fees during the three months ended March 31, 2022 and 2021 were $ 96,250 and $ 96,250 , respectively. Accrued directors’ fees as of March 31, 2022 and December 31, 2021 were $ 1,656,839 and $ 1,560,589 , respectively.

Stockholders_ Deficiency

Stockholders’ Deficiency	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders’ Deficiency	8. Stockholders’ Deficiency Preferred Stock During the three months ended March 31, 2022, the Company issued 52,411 shares of restricted Series D-1 Convertible Preferred Stock in exchange for an investment of $ 150,000 from a non-related party investor.

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases
Leases	9. Leases The Company currently leases 4,500 square feet of corporate office space in Knoxville, Tennessee through an operating lease agreement for a term of five years ending on June 30, 2022 . Payments are approximately $ 6,100 per month. On February 23, 2022, the Company negotiated a continued reduced rent from January 1, 2022 through June 30, 2022 in the amount of $ 6,100 per month. Total operating lease expense for the three months ended March 31, 2022 was $ 14,959 , of which, $ 9,973 was included within research and development and $ 4,986 was included within general and administrative expenses on the condensed consolidated statement of operations. Total operating lease expense for the three months ended March 31, 2021 was $ 24,762 , of which, $ 16,508 was included within research and development and $ 8,254 was included within general and administrative expenses on the condensed consolidated statement of operations. A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities For The Three Months Ended March 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 18,447 $ 23,831 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 3 1 year 3 months Weighted Average Discount Rate Operating leases 8.0 % 8.0 % Future minimum payments under the Company’s non-cancellable lease obligations as of March 31, 2022 were as follows: Schedule of Future Minimum Payments Under Non-cancellable Lease Years Amount 2022 $ 18,447 Total future minimum lease payments 18,447 Less: amount representing imputed interest (234 ) Total $ 18,203

Grants

Grants	3 Months Ended
	Mar. 31, 2022
Revenue Recognition and Deferred Revenue [Abstract]
Grants	10. Grants On October 25, 2021, the Company received a grant award of $ 2,500,000 2,312,395 187,605

Commitments, Contingencies and

Commitments, Contingencies and Litigation	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Litigation	11. Commitments, Contingencies and Litigation The Company may, from time to time, be involved in litigation arising in the ordinary course of business or which may be expected to be covered by insurance. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events The Company has evaluated events that have occurred after the balance sheet and through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below. Subsequent to March 31, 2022, the Company entered into a 2021 Note with a non-related party investor in the aggregate principal amount of $ 500,000 Subsequent to March 31, 2022, the Company announced it has added Aru Narendran, MD, PhD at the University of Calgary to the Scientific Advisory Board.

Significant (Policies)

Significant (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In October 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-10 “Codification Improvements” On May 3, 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. As of March 31, 2022 and December 31, 2021, the Company’s cash equivalents consist of Treasury bills of $ 42,594 .
Restricted Cash	Restricted Cash Restricted cash consists of a grant award of $ 2,500,000 192,605
Cash Concentrations	Cash Concentrations Cash, cash equivalents, and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $ 250,000 2,231,009 2,856,942
Reclassifications	Reclassifications Certain prior year balances have been reclassified in order to conform to current year presentation. These reclassifications had no effect on previously reported results of operations or loss per share.
Basic and Diluted Loss Per Common Share	Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares March 31, March 31, 2022 2021 Warrants 512,500 82,764,164 Options 3,625,000 4,800,000 Convertible preferred stock 105,081,847 65,666 2021 unsecured convertible notes 5,436,408 - Total potentially dilutive shares 114,655,755 87,629,830

Significant (Tables)

Significant (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares	Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares March 31, March 31, 2022 2021 Warrants 512,500 82,764,164 Options 3,625,000 4,800,000 Convertible preferred stock 105,081,847 65,666 2021 unsecured convertible notes 5,436,408 - Total potentially dilutive shares 114,655,755 87,629,830

Other Accrued Expenses (Tables)

Other Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Schedule of Other Accrued Expenses	The following table summarizes the other accrued expenses at March 31, 2022 and December 31, 2021: Schedule of Other Accrued Expenses March 31, 2022 December 31, 2021 Accrued payroll and taxes $ 244,349 $ 174,533 Accrued vacation 50,859 42,871 Accrued directors’ fees 1,656,839 1,560,589 Accrued other expenses 233,714 224,493 Total Other Accrued Expenses $ 2,185,761 $ 2,002,486

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Schedule of Convertible Notes Payable Non-Related Party Related Party Face Amount Face Amount Total Balance as of January 1, 2022 $ 1,260,000 $ 200,000 $ 1,460,000 Issued 50,000 - 50,000 Balance as of March 31, 2022 $ 1,310,000 $ 200,000 $ 1,510,000

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases
Schedule of Right-of-use Assets and Liabilities	A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities For The Three Months Ended March 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 18,447 $ 23,831 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 3 1 year 3 months Weighted Average Discount Rate Operating leases 8.0 % 8.0 %
Schedule of Future Minimum Payments Under Non-cancellable Lease	Future minimum payments under the Company’s non-cancellable lease obligations as of March 31, 2022 were as follows: Schedule of Future Minimum Payments Under Non-cancellable Lease Years Amount 2022 $ 18,447 Total future minimum lease payments 18,447 Less: amount representing imputed interest (234 ) Total $ 18,203

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$ 2,481,009	$ 3,106,942	$ 349,771	$ 97,231
Restricted Cash	2,307,395
Working capital	$ 5,112,713	$ 4,258,679

Schedule of Securities Excluded

Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	114,655,755	87,629,830
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	512,500	82,764,164
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	3,625,000	4,800,000
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	105,081,847	65,666
2021 Unsecured Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	5,436,408

Significant (Details Narrative)

Significant (Details Narrative) - USD ($)	Oct. 25, 2021	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Cash Equivalent - Treasury Bills		$ 42,594	$ 42,594
Proceeds from grant	$ 2,500,000
Payment to vendors for expense	$ 192,605
Insured limits		250,000
Cash in excess FDIC insured amount		$ 2,231,009	$ 2,856,942

Schedule of Other Accrued Expen

Schedule of Other Accrued Expenses (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued payroll and taxes	$ 244,349	$ 174,533
Accrued vacation	50,859	42,871
Accrued directors’ fees	1,656,839	1,560,589
Accrued other expenses	233,714	224,493
Total Other Accrued Expenses	$ 2,185,761	$ 2,002,486

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - Convertible Notes Payable	3 Months Ended
	Mar. 31, 2022USD ($)
Short-Term Debt [Line Items]
Balance as of January 1, 2022	$ 1,460,000
Issued	50,000
Balance as of March 31, 2022	1,510,000
Non-Related Party [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2022	1,260,000
Issued	50,000
Balance as of March 31, 2022	1,310,000
Related Party [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2022	200,000
Issued
Balance as of March 31, 2022	$ 200,000

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Short-Term Debt [Line Items]
Proceeds from note payable	$ 50,000	$ 1,200,000
2021 Note [Member]
Short-Term Debt [Line Items]
Proceeds from note payable	1,510,000
Proceeds from related party investor	$ 200,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Note payable	$ 154,925	$ 238,452

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Related Party Transaction [Line Items]
Accrued directors fees	$ 1,656,839		$ 1,560,589
Salary and Wage, Officer, Excluding Cost of Good and Service Sold	96,250	$ 96,250
Mr Bruce Horowitz [Member]
Related Party Transaction [Line Items]
Professional fees	42,400	84,800
Accrued directors fees	300,000		281,250
Director [Member] | Mr Bruce Horowitz [Member]
Related Party Transaction [Line Items]
Professional fees	18,750	$ 18,750
Director [Member] | Mr Bruce Horowitz [Member] | Capital Strategists [Member]
Related Party Transaction [Line Items]
Professional fees	$ 127,200		$ 127,200

Stockholders_ Deficiency (Detai

Stockholders’ Deficiency (Details Narrative) - Restricted Series D-1 Preferred Stock [Member] - Investor [Member]	3 Months Ended
	Mar. 31, 2022USD ($)shares
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues | shares	52,411
Stock Issued During Period, Value, New Issues | $	$ 150,000

Schedule of Right-of-use Assets

Schedule of Right-of-use Assets and Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases	$ 18,447	$ 23,831
Right-of-use assets obtained in exchange for lease obligations: Operating leases
Weighted Average Remaining Lease Term: Operating leases	3 months	1 year 3 months
Weighted Average Discount Rate: Operating leases	8.00%	8.00%

Schedule of Future Minimum Paym

Schedule of Future Minimum Payments Under Non-cancellable Lease (Details)	Mar. 31, 2022USD ($)
Leases
2022	$ 18,447
Total future minimum lease payments	18,447
Less: amount representing imputed interest	(234)
Total	$ 18,203

Leases (Details Narrative)

Leases (Details Narrative)	3 Months Ended		6 Months Ended
	Mar. 31, 2022USD ($)ft²	Mar. 31, 2021USD ($)	Jun. 30, 2022USD ($)
Research and Development Expense [Member]
Operating Lease, Expense	$ 9,973	$ 16,508
General and Administrative Expense [Member]
Operating Lease, Expense	4,986	8,254
Property Subject to Operating Lease [Member]
Operating Lease, Expense	$ 14,959	$ 24,762
Forecast [Member]
[custom:ReducedPaymentsForRent]			$ 6,100
Knoxville, Tennessee [Member]
Area of Land | ft²	4,500
Lessee, Operating Lease, Term of Contract	5 years
Lease Expiration Date	Jun. 30, 2022
Payments for Rent	$ 6,100

Grants (Details Narrative)

Grants (Details Narrative) - USD ($)	Oct. 25, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Revenue Recognition and Deferred Revenue [Abstract]
Proceeds from grant award for study of animal cancer and dermatological	$ 2,500,000
Unearned grant revenue liability		$ 2,312,395		$ 2,500,000
Grant revenue		$ 187,605

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	May 12, 2022USD ($)
Subsequent Event [Member] | Two Thousand And Twenty One Note [Member] | Non Related Party Investor [Member]
Subsequent Event [Line Items]
Proceeeds from loan	$ 500,000